Travere Therapeutics, Inc.
https://travere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Travere Therapeutics, Inc.
Novartis Bookends October With Two IgAN Successes
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.
Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
Muted APPLAUSE For Novartis In IgAN
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss
The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Desert Gateway, Inc.
- Kyalin Biosciences, Inc.
- Manchester Pharmaceuticals LLC.
- Orphan Technologies Ltd.
- Retrophin, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice